FILTER
LATEST INTERVIEWS
Diogo Mac Cord de Faria
NATIONAL SECRETARY OF INFRASTRUCTURE DEVELOPMENT, MINISTRY OF THE ECONOMY, GOVERNMENT OF BRAZIL
The Government of Brazil looks to reduce logistics bottlenecks as part of its wider strategy to grow its GDP from 1.7% to 4% by 2022.
Fernando Figueiredo
CEO, ABIQUIM (ASSOCIAÇÃO BRASILEIRA DA INDÚSTRIA QUÍMICA)
ABIQUIM is implementing a multifaceted strategy to increase the competitiveness of Brazil’s chemical industry.
José M. Berges
CEO, GTM HOLDINGS
GTM is highly focused on M&A to grow its presence and capabilities in Latin America.
Alex Holmes
CEO, PLATEAU ENERGY METALS
Plateau Energy Metals is a Canadian lithium and uranium exploration and development company focused on its properties in southeastern Peru.
Jorge Buckup
PRESIDENT LATIN AMERICA, UNIVAR SOLUTIONS
Univar Solutions is expanding its business in the Latin America region through a series of acquisitions.
João Parolin
CEO, OXITENO
Chemical manufacturing company Oxiteno is exploting opportunities in the United States while maintaining an eye on economic recovery in Latin America.
Nicole Bishop
CEO AND FOUNDER, QUARTOLIO
Quartolio is an AI-powered knowledge management platform that accelerates research by connecting the dots across scholarly data, documents and discussions.
Hon. Bill Johnston
MINISTER FOR MINES AND PETROLEUM, DEPARTMENT OF MINES AND PETROLEUM, GOVERNMENT OF WESTERN AUSTRALIA
The WA government remains committed to fostering a favorable investment environment.
Liam Morrissey
CEO, MS RISK
MS Risk identifies, mitigates and reduces security risk to protect client assets around the world and across several sectors.
Silvia Rosas
PRESIDENT, PROEXPLO
ProExplo is one of the key geological-mining meetings in Latin America that brings together government, industry leaders and explorers.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
